| Literature DB >> 34681906 |
Yu-Sheng Lin1,2, Tzu-Hao Chang3, Wan-Chun Ho1, Shun-Fu Chang4, Yung-Lung Chen5, Shih-Tai Chang1, Huang-Chung Chen5, Kuo-Li Pan1, Mien-Cheng Chen5.
Abstract
The most common ventricular premature contractions (VPCs) originate from the right ventricular outflow tract (RVOT), but the molecular mechanisms of altered cytoskeletons of VPC-induced cardiomyopathy remain unexplored. We created a RVOT bigeminy VPC pig model (n = 6 in each group). Echocardiography was performed. The histopathological alternations in the LV myocardium were analyzed, and next generation sequencing (NGS) and functional enrichment analyses were employed to identify the differentially expressed genes (DEGs) responsible for the histopathological alternations. Finally, a cell silencing model was used to confirm the key regulatory gene and pathway. VPC pigs had increased LV diameters in the 6-month follow-up period. A histological study showed more actin cytoskeleton disorganization and actin accumulation over intercalated disc, Z-line arrangement disarray, increased β-catenin expression, and cardiomyocyte enlargement in the LV myocardium of the VPC pigs compared to the control pigs. The NGS study showed actin cytoskeleton signaling, RhoGDI signaling, and signaling by Rho Family GTPases and ILK Signaling presented z-scores with same activation states. The expressions of Rac family small GTPase 2 (Rac2), the p-cofilin/cofilin ratio, and the F-actin/G-actin ratio were downregulated in the VPC group compared to the control group. Moreover, the intensity and number of actin filaments per cardiomyocyte were significantly decreased by Rac2 siRNA in the cell silencing model. Therefore, the Rac2/cofilin pathway was found to play a crucial role in the sarcomere morphology and Z-line arrangement disarray induced by RVOT bigeminy VPCs.Entities:
Keywords: Rac2/cofilin; actin cytoskeleton signaling; cardiomyopathy; sarcomere; ventricular premature contraction
Mesh:
Substances:
Year: 2021 PMID: 34681906 PMCID: PMC8541677 DOI: 10.3390/ijms222011244
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Heart weight, left ventricular mass, left ventricular size, and left ventricular ejection fraction between the RVOT-VPC group and the sham control group at baseline and 6-month follow-up. Heart weight of the RVOT-VPC group was bigger than the sham control group at the 6-month follow-up (p < 0.001) (A). The left ventricular end-diastolic diameter (LVEDD) of the RVOT-PVC group at the 6-month follow-up was significantly larger than that of the RVOT-PVC group at the baseline (p = 0.0022) and that of the sham control group at the 6-month follow-up (p = 0.0101) (B). The LV mass index of the RVOT-VPC group was significantly higher than that of the sham control group at the 6-month follow-up (p = 0.041) (C). There was a trend toward lower LV ejection fraction (LVEF) in the RVOT-PVC group compared to the sham control group at the 6-month follow-up (D). *: p < 0.05; ***: p < 0.001. Blue line to express the trend of difference between Sham control and RVOT-PVC groups at baseline; Red line to express the trend of difference between Sham control and RVOT-PVC groups at the 6-month follow-up.
Figure 2Elevated serum cardiac troponin I level and cardiomyocyte enlargement developed in left ventricular myocardium following 6-month RVOT bigeminy VPCs. (A) Before VPC creating, serum cardiac troponin I levels were similar between RVOT-VPC group and sham control group. However, the RVOT-VPC group had higher serum cardiac troponin I level than the sham control group at the 6-month follow-up, although the difference did not reach statistical significance. The changes in cardiac troponin I level in the RVOT VPC group and sham control group were illustrated by the slopes of the red line and blue line, respectively. (B) Immunofluorescence study with wheat germ agglutinin stain for the cell membrane of cardiomyocytes showed that the RVOT-VPC group had significantly larger cardiomyocyte size than the sham control group at both the left ventricular septum (LVS) (p = 0.0043) and LV free wall (LVFW) (p = 0.0041). Round dot: Sham control group; Square dot: RVOT-VPC group. Each datum in this figure represents the average of 1000 cells per sample. MCSA: myocyte cross-sectional area. Scale bar = 75 μm. *: p < 0.05; **: p < 0.01.
Figure 3Sarcomere morphology, shear angle at the Z-line and the distance between two Z-lines following 6-month RVOT bigeminy VPCs. (A) Immunohistological studies of left ventricular septal and free wall myocardial tissue showed organized sarcomeres (homogenous distribution of F-actin in the sarcomeres, Z-lines in parallel, and equal distance between Z-lines (stained with α-actinin)) in the sham control group but showed that the sarcomere morphology and Z-line arrangement became disarrayed (non-homogenous distribution of F-actin in the sarcomeres and Z-lines not in parallel and different distances between two Z-lines) and spindle-shaped actin accumulations (white arrow) in the RVOT-VPC group. (B–D). The distance between two Z-lines (sarcomere length) and the shear angle at the Z-line (an indicator of reduced Z-direction contraction) were significantly increased in the cardiomyocytes of RVOT-VPC group compared to sham control group at both locations of left ventricle. The length of sarcomeres was measured as the distance between neighboring Z-lines, i.e., the distance between the neighboring peak immunofluorescent intensities of α-actinin (C). The shear angle at the Z-line was defined as the angle between Z-line and the line parallel to the actin in the same sarcomere, i.e., the angle between α-actinin and F-actin (D). DAPI staining for nuclei. Scale bar = 10 μm. ***: p < 0.001.
Figure 4Immunohistological and immunoblotting studies of the expression of β-catenin in the RVOT-VPC group and sham control group at left ventricular septum (LVS A,C) and left ventricular free wall (LVFW B,D. The expression of β-catenin at intercalated discs significantly increased in the RVOT-VPC group than in the sham control group at LVS (A,C) and LVFW (B,D). In addition, the spindle-shape actin accumulation was located at the intercalated discs with β-catenin (insert) (white arrow at right upper panel in (A,B). DAPI staining for nuclei. Scale bar = 10 μm. *: p < 0.05 and **: p < 0.01. PC: positive control.
Log2 fold change values and predictive activity of the differentially expressed genes significantly involved in the actin cytoskeleton signaling pathway.
| Tissue | Pathways | Symbol | Entrez Gene Name | Z Score | Log2FC Value | Predictive Activity to Pathway (IPA Knowledge Base) |
|---|---|---|---|---|---|---|
|
| Actin Cytoskeleton Signaling | ACTG2 | actin, gamma 2, smooth muscle, enteric | −1.265 | −2.112 | Activation |
| CYFIP2 | cytoplasmic FMR1 interacting protein 2 | 0.855 | - | |||
| FGF16 | fibroblast growth factor 16 | 2.58 | - | |||
| ITGA4 | integrin subunit alpha 4 | −1.28 | Activation | |||
| RAC2 | Rac family small GTPase 2 | −0.876 | Activation | |||
| Signaling by Rho Family GTPases | ACTG2 | actin, gamma 2, smooth muscle, enteric | −1.508 | −2.112 | Activation | |
| CDH12 | cadherin 12 | 2.135 | Activation | |||
| CDH24 | cadherin 24 | −1.45 | Activation | |||
| GNB3 | G protein subunit beta 3 | 1.457 | - | |||
| ITGA4 | integrin subunit alpha 4 | −1.28 | Activation | |||
| RhoGDI Signaling | ACTG2 | actin, gamma 2, smooth muscle, enteric | 0.333 | −2.112 | inhibition | |
| CDH12 | cadherin 12 | 2.135 | inhibition | |||
| CDH24 | cadherin 24 | −1.45 | inhibition | |||
| GNB3 | G protein subunit beta 3 | 1.457 | - | |||
| ITGA4 | integrin subunit alpha 4 | −1.28 | inhibition | |||
| ILK Signaling | ACTG2 | actin, gamma 2, smooth muscle, enteric | −1.414 | −2.112 | Activation | |
| FBLIM1 | filamin binding LIM protein 1 | 0.636 | - | |||
| MMP9 | matrix metallopeptidase 9 | −2.105 | - | |||
| LXR/RXR Activation | ARG2 | arginase 2 | 2.646 | 1.931 | Activation | |
| MMP9 | matrix metallopeptidase 9 | −2.105 | inhibition | |||
| S100A8 | S100 calcium binding protein A8 | −3.753 | inhibition | |||
| SERPINF1 | serpin family F member 1 | 1.384 | Activation | |||
| Cardiac Hypertrophy Signaling | ADRB2 | adrenoceptor beta 2 | −0.632 | 0.804 | Activation | |
| CACNA1S | calcium voltage-gated channel subunit alpha1 S | −4.149 | Activation | |||
| GNB3 | G protein subunit beta 3 | 1.457 | Activation | |||
|
| Actin Cytoskeleton Signaling | ACTG2 | actin, gamma 2, smooth muscle, enteric | −1.633 | −2.595 | Activation |
| CYFIP2 | cytoplasmic FMR1 interacting protein 2 | 1.046 | - | |||
| FGF16 | fibroblast growth factor 16 | 1.397 | - | |||
| ITGA4 | integrin subunit alpha 4 | −0.937 | Activation | |||
| RAC2 | Rac family small GTPase 2 | −0.814 | Activation | |||
| Signaling by Rho Family GTPases | ACTG2 | actin, gamma 2, smooth muscle, enteric | −0.632 | −2.595 | Activation | |
| CDH12 | cadherin 12 | 1.983 | Activation | |||
| CDH24 | cadherin 24 | −1.144 | Activation | |||
| GNB3 | G protein subunit beta 3 | 0.991 | - | |||
| ITGA4 | integrin subunit alpha 4 | −0.937 | Activation | |||
| RhoGDI Signaling | ACTG2 | actin, gamma 2, smooth muscle, enteric | 0.707 | −2.595 | inhibition | |
| CDH12 | cadherin 12 | 1.983 | inhibition | |||
| CDH24 | cadherin 24 | −1.144 | inhibition | |||
| GNB3 | G protein subunit beta 3 | 0.991 | - | |||
| ITGA4 | integrin subunit alpha 4 | −0.937 | inhibition | |||
| ILK Signaling | ACTG2 | actin, gamma 2, smooth muscle, enteric | −1.134 | −2.595 | Activation | |
| FBLIM1 | filamin binding LIM protein 1 | 0.625 | - | |||
| MMP9 | matrix metallopeptidase 9 | −5.142 | - | |||
| LXR/RXR Activation | ARG2 | arginase 2 | −0.632 | 1.951 | Activation | |
| MMP9 | matrix metallopeptidase 9 | −5.142 | inhibition | |||
| S100A8 | S100 calcium binding protein A8 | −3.185 | inhibition | |||
| SERPINF1 | serpin family F member 1 | 0.963 | Activation | |||
| Cardiac Hypertrophy Signaling | ADRB2 | adrenoceptor beta 2 | 1.265 | 0.800 | Activation | |
| CACNA1S | calcium voltage-gated channel subunit alpha1 S | −3.299 | Activation | |||
| GNB3 | G protein subunit beta 3 | 0.991 | Activation |
Figure 5Five differentially expressed genes related to actin cytoskeleton signaling induced by 6-month RVOT bigeminy VPCs in the septum and free wall of left ventricle. Five genes that were differentially upregulated or downregulated in the RVOT-VPC group compared to the sham control group according to next generation sequencing analysis results were selected and studied. The expressions of RAC2, ACTG2, and ITGA4 were downregulated while the expressions of CYFIP2 and FGF16 were upregulated in the RVOT-VPC group compared to sham control group. *: p < 0.05 and **: p < 0.01.
Figure 6The expression of Rac2, phosphorylation of cofilin and F-actin/G-actin ratio in the LV myocardium following 6-month RVOT bigeminy VPC. Immunoblotting study showed that the expressions of (A) Rac family small GTPase 2 (Rac2), (B) Ratio of p-cofilin/cofilin, and (C) F-actin/G-actin ratio in left ventricular (LV) septum and LV free wall were significantly decreased in the RVOT bigeminy VPC group compared to the sham control group at the 6-month follow-up. *: p < 0.05; **: p < 0.01. PC: positive control.
Figure 7The expression of the Rac2, ratio of p-cofilin/cofilin and F-actin in the rat ventricular cardiomyocytes after silencing Rac2 gene. After silencing Rac2, the expression of Rac2 protein in the rat ventricular cardiomyocytes was significantly decreased compared to the control group (siCTL) without silencing Rac2 by immunoblotting study (A). The ratio of p-cofilin/cofilin in the rat ventricular cardiomyocytes was significantly lower in the siRac2 rat ventricular cardiomyocytes than the siCTL group (B). Flow cytometric study showed the mean fluorescence intensity (MFI) of F-actin was significantly lower in the siRac2 rat ventricular cardiomyocytes compared to the siCTL group (C). *: p < 0.05 and ***: p < 0.001. PC: positive control.
Figure 8The expression of actin filament in terms of intensity and number of actin filaments in the rat ventricular cardiomyocytes with and without silencing Rac2 gene by confocal immunofluorescence study. (A) Silencing Rac2 gene to suppress Rac2 expression significantly changed the actin distribution in the rat ventricular cardiomyocytes. ß-catenin staining for cell membrane; DAPI staining for nuclei. (B) Three 10-μm lines were drawn at equal distance at three separate parts of cardiomyocyte and the mean immunofluorescence intensity and number of immunofluorescence peaks were calculated by using ImageJ (spot function) and these values were measured from 100 individual cells per sample in each of the four repeated experiments. (C) The intensity of actin (F-actin) and number of actin myofilaments per cardiomyocyte were significantly decreased by Rac2 siRNA. Scale bar = 20 μm. ***: p < 0.001.